

PLENARY SESSION

AGENDA

TIME	TOPIC
7:00-8:00	• Check in and free networking
8:00-8:20	• Opening Remarks Xinxin Li, VP of Strategic Partnerships, MyBioGate
8:20-9:20	• Keynote speeches Discovering HER2, Herceptin – And Opportunities for Future Breakthroughs through Global-American-Chinese Research Collaboration – 2019 Lasker Award winner; Herceptin inventor, H. Michael Shepard Global life science and healthcare investment and finance 2019 – Katherine Andersen, Head of Life Science & Healthcare, Silicon Valley Bank
9:20-10:50	• Chinese companies' road to world-class corporations Moderator: Helen Chen – Greater China Managing Partner, L.E.K. Consulting Internationalization of Chinese companies in Healthcare – Dajian Cai, GTJA Investment Group Phoenix Reborn--Innovative R&D Strategy and Plan of Gloria Biosciences – Helena Meng, VP and CMO, Gloria Biosciences Rising China Biotech: The CStone Story – Shirley Zhao, CStone Pharma Opportunities and challenges in China healthcare market – Helen Chen, L.E.K. Consulting Fireside chat Dajian Cai – Chairman, GTJA Investment Group Shirley Zhao – Great China General Manager & Head of Commercial, CStone Pharma Austin Zhu – President of Gloria Pharmaceuticals, General Manager of Gloria Biosciences
10:50-11:40	• Panel 1 – New landscape and trends of investment in life science & healthcare Moderator: Kim Nearing – Venture Partner, BVCF Management, Ltd. Panelists: James Huang – Founding Partner, Panacea Venture; Managing Partner, KPCB China Amy Tang – Venture Partner, Qiming Venture Partners Bo Liu – Executive VP & Managing Director- Healthcare Investments, CDIB Capital John Zhu – Partner, 6 Dimensions Capital Mark Tang – Managing Director, Good Health Capital Wendy Pan – Partner, Goodwin LLP
11:50-12:30	• Medical device elevator pitch (Company Info on page 9)
12:30-13:30	• Lunch Break
13:30-14:15	• Panel 2 – China market needs for medical devices Moderator: Tianji Zhu, VP, CD Capital Panelists: Yonghui Shi – Managing Director, Metronic China Fund Adam Zhao – Partner, Anlong Fund Yu Fang – Partner, 3E Bioventures Capital Drake Yu – Founding Partner, LYFE Capital
14:15-15:00	• Fireside Chat – MNCs' strategies to meet new opportunities and challenges in the China market Moderator: Dennis Purcell – Founder and Senior Advisor, Aisling Capital Guest speakers: Wei Jiang – Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC; President, Bayer Group Greater China
15:00-15:15	• Introduction of Nanjing Jiangbei New Area Chanmei Chen – Executive Deputy Director of Nanjing Municipal Jiangbei New Area Administrative
15:15-15:30	• Break
15:30-16:15	• Panel 3 – Market needs and access in China (Panel Partner: BioKatalyst) Moderator: Paul Zhang – Partner, Bluestar Bioadvisors LLC; President, BioKatalyst Panelists: Bing Yuan – Chief Business Officer, Cstone Pharmaceuticals Zhimin Jimmy Zhang – Venture Partner, Lilly Asia Ventures Derek Small - Founding General Manager, Assembly Biosciences Research & Development Co. Shanghai Jonathan Wang – Senior VP Head, Business Development, Zai Lab Lingyun Dong – General Manager, Yeedozencom Science & Technology
16:15-17:00	• Panel 4 – Chinese pharma' s overseas outreach and collaboration Moderator: Jun Bao – President and CEO, Impact Therapeutics Panelists: Geoffrey Gao – Executive VP/Deputy GM, Harbin Pharmaceutical Group Larry Cai – Executive Director of BD, Fosun pharma Xiangbin Xu – President, Simcere Innovation Center Brad Loncar – CEO, Loncar Investments Lu Cao - US Head of Corporate Banking for Chinese Multinationals, J.P. Morgan

BREAKOUT A

AGENDA

TIME	TOPIC
	Morning: AI and Digital health
11:00—12:00	AI and novel therapeutic solutions Moderator: Echo Hindle-Yang – CEO at M.S.Q. Ventures Panelists: Hainian Zeng – CEO, Silexon AI Technology Alan Jiang – CSO, XtalPi Andrew Radin – CEO, twoXAR Guo-liang Yu – Global CEO, Apollomics Inc Daniel Teper – Co-Founder, Chairman & CEO, CYTOVIA Therapeutics
	Afternoon: Session sponsored by YEEDOZENCOM
13:30-14:00	Interpretation of the Latest Pharmaceutical Administration Law of the People's Republic of China and Provisions for Drug Registration. Zhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.
14:00-14:15	Introduction of YEEDOZENCOM Lingyun Dong – General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.
14:15-15:00	Route Exploration of the Drug Marketing Authorization in China Moderator: Lingyun Dong – General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd. Panelists: Zhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd. Xiumin Huo – Professor of YEEHONG Business School Zhi Xiao – Managing Director, SDIC Fund Zhenyu Li – Business Development Director of LUNAN PHARMACEUTICAL GROUP CORP.
15:00-15:30	Tea Break
15:30-16:00	Q&A for Medicine Launching Regulations in China Market Zhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.

BREAKOUT B

AGENDA

TIME	TOPIC																								
	Morning: Cell and Gene therapy																								
10:00-11:00	Technological bottlenecks and breakthroughs in cell and gene therapy Moderator: Alain Vertès – Managing Director, NxR Biotechnologies GmbH Panelists: Zhenhua Wu – CEO, Exegensis Bio Lynnet Koh – CEO, Targazyme Jason Slingby – CBO, Oxford Biomedica Frank Zhang – CEO, GenScript																								
	Innovation in Jiangsu																								
11:10-11:40	Jiangsu Industrial Technology Research Institute (JITRI) Introduction Paul E. Burrows - Vice President of Jiangsu Industrial Technology Research Institute																								
11:40-11:50	JITRI Southern California Innovation Center Introduction Calvin Chen - CEO of CrossLinkBio, Inc.																								
12:00-13:00	Lunch networking with Jiangsu companies and investors																								
13:00-13:20	Jiangsu Innovative Healthcare Companies Introduction																								
13:30-14:30	Projects Partnering																								
14:30-18:00	Medical device company presentation																								
	<table><tr><td>14:30 - 15:40</td><td>15:50 - 16:50</td><td>17:00 - 17:50</td></tr><tr><td>TomoWave Laboratories</td><td>PhysioCue, Inc.</td><td>Abilitech Medical, Inc.</td></tr><tr><td>Brainstorm Medical Inc.</td><td>PhotoniCare, Inc.</td><td>Aevumed Inc.</td></tr><tr><td>Fibralign Corporation</td><td>Replication Medical, Inc.</td><td>TriReme Medical</td></tr><tr><td>Yolia Health</td><td>Cosm Medical</td><td>iHear Medical</td></tr><tr><td>Pacific Diabetes Technologies</td><td>Nanochon, LLC.</td><td></td></tr><tr><td>ThermopeutiX, Inc.</td><td>Eyedetec Medical, Inc.</td><td></td></tr><tr><td>Vave Health, Inc</td><td></td><td></td></tr></table>	14:30 - 15:40	15:50 - 16:50	17:00 - 17:50	TomoWave Laboratories	PhysioCue, Inc.	Abilitech Medical, Inc.	Brainstorm Medical Inc.	PhotoniCare, Inc.	Aevumed Inc.	Fibralign Corporation	Replication Medical, Inc.	TriReme Medical	Yolia Health	Cosm Medical	iHear Medical	Pacific Diabetes Technologies	Nanochon, LLC.		ThermopeutiX, Inc.	Eyedetec Medical, Inc.		Vave Health, Inc		
14:30 - 15:40	15:50 - 16:50	17:00 - 17:50																							
TomoWave Laboratories	PhysioCue, Inc.	Abilitech Medical, Inc.																							
Brainstorm Medical Inc.	PhotoniCare, Inc.	Aevumed Inc.																							
Fibralign Corporation	Replication Medical, Inc.	TriReme Medical																							
Yolia Health	Cosm Medical	iHear Medical																							
Pacific Diabetes Technologies	Nanochon, LLC.																								
ThermopeutiX, Inc.	Eyedetec Medical, Inc.																								
Vave Health, Inc																									

COMPANY PRESENTATION

TIME	SESSION
10:00-10:05	Opening Ginger Ding, Director of Investment Analyst, MyBioGate
10:05-12:30	Company Presentation Torbjorn Furuseth, CFO, Targovax Lu Wang, Vice President, Flow Pharma Ben Bobo, Founder & CEO, Cerenetx Ping Rawson, Chief Financial Officer, Dyadic International Franz Gruz, CEO, Maintect GmbH Zhijun Zhang, CSO, Zhimeng Biopharma Anna Sumeray, CEO, Virometix Wen Luo, Denovo Biopharma Scott Christensen, CEO, OncoGenesis George Simeon, CEO, Curevo Vaccine Lucy Lu, CFO, Suzhou Kintor Pharmaceuticals
12:30-13:30	Lunch Break
13:30-14:30	Company Presentation Huiru (Jane) Wang, CEO, Huirui Biopharma Michael Tardugno, CEO, Celsion Liming Yang, CEO, Wyze Biotech Mark Colbrie, CEO, Strateos
14:30-15:15	Gain Insights in Dealmaking by Hearing Real World Case Studies Zhenhua Wu, CEO, Exegenesis Bio David Poon, Vice President of Business Development, Zymeworks Shawn Zhang, VP, Ambrx Anu Balendran, Vice President Business Development, Alligator Bioscience Darrin Crisitello, Chief Commercial Officer, Mission Bio James Lee, Sr. Business Development Manager, Atomwise
15:15-17:30	Company Presentation Haijin Meng, Vice President, Chief Medical Officer, Gloria Biosciences Sean Hu, CEO, Avotres Peter Fedichev, CEO, Gero Ying Chen, Senior Vice President of Marketing, Bayer Pharmaceuticals Jiang Li, CEO, VivaLNK Henry Oconnell, CEO, Canary Speech Patrick Lopath, Co-founder and COO, TECLens, LLC Chris Lai, CEO, METiS Pharmaceuticals Mahmoud Rafea, Chief Scientist, Erythra

Kintor Pharmaceutical Limited:

Kintor is a clinical-stage novel drugs developer in China focusing on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other AR-related (antrogen receptor) diseases. It had developed five clinical-stage drug candidates. The lead product, Proxalutamide, is a potential best-in-class drug undergoing phase III clinical trials in China and phase II clinical trials in US for mCRPC as well as clinical trials for breast cancer. Kintor's mission is to become a global leader in the research, development and commercialisation of innovative therapies, focusing on indications with substantial unmet medical needs, in particular in the AR-related field.